Foundayo (Orforglipron) Pill

Foundayo is a once-daily weight loss tablet containing the active ingredient orforglipron. It belongs to a group of medicines called GLP-1 receptor agonists, which help reduce appetite and increase feelings of fullness.

Unlike many existing GLP-1 weight loss treatments, Foundayo is taken as a tablet rather than an injection. It can be taken at any time of day, with or without food, giving patients greater flexibility around when they take their treatment.

Foundayo is prescribed alongside a reduced-calorie diet and increased physical activity to support long-term weight loss and weight management.

The active ingredient in Foundayo is orforglipron.

Orforglipron is a small-molecule GLP-1 receptor agonist. Its structure allows it to be absorbed through the digestive system without the strict fasting requirements associated with some other oral GLP-1 treatments.

Foundayo is the brand name of the medicine, while orforglipron is the active ingredient it contains.

Foundayo is taken once a day and treatment begins at a low dose. The dose is gradually increased to help your body adjust to the medicine and reduce the likelihood of side effects.

The Foundayo dose progression is:

0.8mg → 2.5mg → 5.5mg → 9mg → 14.5mg → 17.2mg

You will usually remain on each dose for at least 30 days before moving to the next strength.

Not everyone will need to reach the maximum dose. Some people may achieve suitable results on a lower strength, while others may require further dose increases.

Your prescriber will determine the most appropriate dose for you based on how well the treatment is working and how well you tolerate it.

Take one Foundayo tablet once daily.

Swallow the tablet whole. Do not crush, chew or break it.

Foundayo can be taken:

• at any time of day

• with or without food

• without needing to fast before taking it

• without needing to wait before eating afterwards

Although Foundayo can be taken at any time, taking your tablet at approximately the same time each day can help you remember your dose.

This flexibility is one of the main differences between Foundayo and some other oral GLP-1 weight loss medicines, which may need to be taken on an empty stomach and require patients to wait before eating, drinking or taking other medicines.

Foundayo works by mimicking the effects of GLP-1, or glucagon-like peptide-1, a hormone naturally released by your body after eating.

GLP-1 plays an important role in controlling appetite, digestion and blood sugar levels.

By activating GLP-1 receptors, Foundayo can help:

• reduce hunger

• reduce food cravings

• increase feelings of fullness

• slow how quickly food leaves the stomach

• help regulate blood sugar levels after eating

These effects can make it easier to eat smaller portions and reduce your overall calorie intake.

You may not notice the full effect on your appetite immediately. The effects can develop gradually as your body adjusts to treatment and your dose is increased.

Foundayo should be used alongside a balanced, reduced-calorie diet and increased physical activity to support long-term weight management.

Like other GLP-1 weight loss treatments, Foundayo can cause side effects, although not everyone will experience them. The most commonly reported side effects affect the digestive system.

Nausea, diarrhoea and vomiting are particularly common when treatment is first started. These side effects generally become less noticeable over time in most people.

Foundayo is used alongside a reduced-calorie diet and increased physical activity for weight loss and long-term weight management in eligible adults. 

For weight management, Foundayo may be prescribed for adults who initially have:

• a BMI of 30 kg/m² or greater (obesity), or

• a BMI of at least 27 kg/m² but less than 30 kg/m² (overweight) and at least one weight-related health problem.

Weight-related health problems can include:

• prediabetes

• type 2 diabetes

• high blood pressure

• abnormal levels of fats in the blood

• obstructive sleep apnoea

• impaired heart function

• a history of heart attack, stroke or blood-vessel problems

Whether Foundayo is suitable for you will depend on factors including your BMI, current health, medical history and any other medicines you take.

Before treatment is prescribed, a clinician will assess your suitability to make sure Foundayo is an appropriate option for you.

Foundayo is not suitable for everyone.

You should not take Foundayo if you have had a serious allergic reaction to orforglipron or any of the other ingredients contained in the medicine.

You should speak to your doctor, nurse or pharmacist before taking Foundayo if you:

• have or have previously had pancreatitis

• have severe problems with food digestion or food remaining in your stomach for longer than normal, including severe gastroparesis

• have kidney problems

• have gallbladder problems

• have a problem with your eyes or vision, such as diabetic retinopathy or macular oedema

• have or have had severe heart failure

• are taking insulin or a sulfonylurea for diabetes

• are taking medicines for high blood pressure

• are due to have surgery where you will be under anaesthesia

Your healthcare professional can assess whether Foundayo is suitable for you based on your medical history and current medicines.

Foundayo should not be used during pregnancy because its effects on an unborn baby are not known.

If you are pregnant, think you may be pregnant or are planning to have a baby, speak to your doctor before using Foundayo.

If you could become pregnant, it is recommended that you use contraception while taking Foundayo.

Orforglipron may reduce the effectiveness of oral hormonal contraceptives. If you use an oral contraceptive, you should consider using a barrier method of contraception, such as condoms, or switching to a non-oral contraceptive method for 30 days after starting Foundayo and for 30 days after each dose increase.

If you wish to become pregnant, discuss your treatment with your doctor. Foundayo should be stopped at least 3 weeks before trying to become pregnant.

Foundayo should not be used during breastfeeding.

It is not known whether orforglipron passes into breast milk, and a risk to newborns and infants cannot be ruled out.

Speak to your doctor if you are breastfeeding or planning to breastfeed before starting treatment.

If you forget to take Foundayo, take the missed dose as soon as you remember on the same day.

If you do not remember until the following day, skip the missed dose and take your next dose on your usual scheduled day.

Do not take two doses on the same day to make up for a missed dose.

If you miss a dose for more than 7 days, take your next dose on your regularly scheduled day.

If you are unsure what to do after missing a dose, speak to your doctor, pharmacist or clinical team.

Keep Foundayo below 30°C.

Keep the tablets in their original package to protect them from light.

Keep Foundayo out of the sight and reach of children.

Foundayo (orforglipron) has been studied in large clinical trials involving adults living with obesity or overweight.

One of the main studies supporting the use of orforglipron for weight management was ATTAIN-1, a 72-week Phase 3 clinical trial involving 3,127 adults with obesity, or overweight with at least one weight-related health problem, who did not have type 2 diabetes. Participants received orforglipron or placebo alongside a reduced-calorie diet and increased physical activity.

The study found that average weight loss was greater with higher doses of orforglipron:

These results are based on the study's analysis of average percentage change in body weight at 72 weeks. Individual results varied between participants.

The highest dose also produced clinically meaningful improvements in other measures associated with cardiometabolic health, including waist circumference, non-HDL cholesterol, triglycerides and systolic blood pressure.

A separate analysis using an efficacy estimand found an average weight loss of 12.4% after 72 weeks among participants receiving the highest dose. This figure should not be interpreted as a guarantee of the amount of weight an individual will lose.

Weight loss results vary between individuals. Your response to treatment may be affected by factors including your starting weight, dose, diet, physical activity and how your body responds to treatment.

For further information about the ATTAIN-1 results, see the official Foundayo clinical trial information from Eli Lilly.

Foundayo and the Wegovy Pill are both once-daily oral GLP-1 receptor agonist treatments used for weight management,  but they contain different medicines and have different instructions for how they are taken.

Foundayo contains orforglipron, while the Wegovy Pill contains semaglutide.

One of the biggest differences is the flexibility around taking your daily dose.

Foundayo can be taken at any time of day, with or without food.

Wegovy tablets must be taken on an empty stomach after a fasting period of at least 8 hours. The tablet should be swallowed whole with a small amount of water, and you should wait at least 30 minutes before eating, drinking or taking other oral medicines.

These different dosing instructions are related to the way the two medicines are absorbed in the body.

Both orforglipron and oral semaglutide have been studied in clinical trials and have produced significant weight loss when used alongside dietary and physical activity changes.

In the ATTAIN-1 trial, average weight loss after 72 weeks was 11.1% with Foundayo 17.2 mg and 2.1% with placebo.

In the OASIS 4 trial, adults with overweight or obesity without type 2 diabetes who received oral semaglutide 25 mg once daily alongside lifestyle intervention had an estimated average weight reduction of 13.6% after 64 weeks, compared with 2.2% with placebo.

However, these results come from separate clinical trials with different study populations, treatment durations, study designs and medicines. They should therefore not be interpreted as a direct head-to-head comparison of Foundayo and Wegovy tablets.

The most appropriate treatment will depend on factors including your medical history, other medicines, treatment preferences, response to treatment and the dosing requirements of each medicine.

Foundayo can interact with certain medicines, so it is important to tell your clinician about all medicines you are currently taking before starting treatment.

This includes prescription medicines, over-the-counter medicines and supplements.

Foundayo slows the rate at which the stomach empties. This means it may affect how quickly some medicines taken by mouth are absorbed.

Examples of medicines where particular care may be required include:

• insulin

• sulfonylureas or other diabetes medicines

• simvastatin

• oral contraceptive tablets

• certain antibiotics

• certain antifungal medicines

• medicines that affect how drugs are processed by the liver

Taking Foundayo alongside insulin or some diabetes medicines may increase the risk of low blood sugar. Your diabetes medication may therefore need to be reviewed or adjusted.

Some medicines can also increase or decrease the amount of orforglipron in your bloodstream, which may affect how well Foundayo works or increase the likelihood of side effects.

Always provide a complete and accurate list of your current medicines during your consultation so your clinician can check for possible interactions.

If you are due to have surgery or a procedure involving sedation or general anaesthetic, tell your medical team that you are taking Foundayo. GLP-1 medicines can slow stomach emptying, which may be relevant when planning your procedure.